Osteoprotegerin (OPG), which is a biomarker involved in the process of bone remodeling, constitutes a regulation system for bone metabolism together with receptor activator of nuclear factor-κB (RNAK) and RANK ligand (RNAKL). Creative BioMart Biomarker offers high quality detection service for OPG, ensuring high detection accuracy, sensitivity and efficiency for each sample.
Introduction
OPG is an inhibitory factor of osteoclastogenesis, which is also known as a member of the tumor necrosis factor receptor superfamily (TNFRS), it is mainly secreted by osteoblast lineage cells, vascular endothelial cells, B cells and the epithelial cells of gastrointestinal tract, lung, breast and skin. OPG is a glycoprotein which can exist as a 60 kDa monomer or a 120 kDa dimer in soluble form. The monomer of OPG can be linked by disulfide bonds to form the dimer that plays a critical role in bone remodeling process as an activity factor. The dimerization of OPG can increase its affinity for RANKL, while OPG in the form of a monomeric protein cannot inhibit the interaction of RANK-RANKL by competitive binding with RANKL, which is due to its insufficient affinity with RANKL, for these reasons, OPG dimerization is essential for its inhibition of RANK-RANKL. The RANKL/RANK/OPG signaling pathway is discovered in 1990s, RANK is a member of TNFR that constitutively expressed in prostate, liver, osteoclast and other tissue cells, while RANKL is usually expressed in osteoblasts, stromal cells and T cells, OPG act as a decoy receptor to RANKL. RANKL can be bind to RANK that expressed on the surface of preosteoclast to promote the differentiation and maturation of osteoclast, however, OPG blocks the activation of RANKL by binding and neutralizing RNAKL, and results in the inhibition of osteoclastogenesis and promote the apoptosis of osteoclasts. Due to the critical role OPG played in bone remodeling, it can be considered as a biomarker for several bone diseases. For instance, OPG overexpression is related to osteopetrosis as its inhibition function to osteoclast production, on the contrary, OPG deletion is related to osteoporosis as its enhancing for bone remodeling. In addition, the expression level of OPG is higher in patient suffered with cancer, and OPG has the role of promoting angiogenesis, bone metastasis and multiple myeloma. Expression of OPG therefore is coordinated with bone metabolism and regulates bone density with RANK and RANKL.
Figure 1. Hormonal control of bone resorption (Boyle, et al. 2003)
Application of OPG Detection
- Plasma and serum OPG levels as biomarkers to predict different diseases, such as osteopetrosis, osteoporosis, bone metastasis, multiple myeloma, etc.
Our Advantages
- Guarantee high accuracy and sensitivity for OPG detection
- Ensure high repeatability of OPG detection
- Short turn-around time of detection service
- Competitive price in the market of detection services
- Provide multiple OPG detection methods, including ELISA and EIA
- Accept a wide range of sample types (serum and plasma)
Workflow of OPG Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the OPG detection procedure to ensure accurately quantify the level of OPG in each sample.
At Creative BioMart Biomarker, we offer OPG detection service that includes several technical methods, you can communicate with our experts according to your research needs, and we will determine the final detection technological scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.
References:
- Boyle, W.J.; et al. Osteoclast differentiation and activation. Nature. 2003, 423(6937): 337-342.
- Martin, T.J.; Sims, N.A. RANKL/OPG; critical role in bone physiology. Reviews in Endocrine and Metabolic Disorders. 2015, 16(2): 131-139.
